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Murme mammary carcinoma (FM3A TK-/HSV-1 TK+) cells, which are thymidine kinase (TK)-deficient 
but have been transformed with the herpes simplex virus type 1 (HSV-I) TK gene are inhibited in their 
growth by (E)-5-(2-bromovinyl)-2’-deoxyuridine (BVDU), (E)-5-(2-iodovinyl)-2’-deoxyuridine (IVDU) and 
(I?‘)-5-(2-bromovinyl)-2’-deoxycytidine (BVDC) at 0.5, 0.5 and 0.8 ng/ml, respectively; i.e., a concentration 
5000 to 20000-fold lower than that required to inhibit the growth of the corresponding wild-type FM3A/O 
cells. Hence, transformation of tumor cells with the HSV-I TK gene makes them particularly sensitive to 
the cytostatic action of BVDU and related compounds. 
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1. INTRODUCTION 
Recently, several potent and selective antiher- 
petit agents have been developed, i.e. 9-(2-hydrox- 
yethoxymethyl)guanine (acyclovir, ACV) [l], 
9 - [( 1,3 - dihydroxy - 2 - propoxy)methyl]guanine 
(DHPG) [2,3], Q-5-(2-bromovinyl)-2’-deoxyuri- 
dine (BVDU) [4] and its closely related analogues 
(E)-5-(2-iodovinyl)-2’-deoxyuridine (IVDU) [4], 
(E)-5-(2-bromovinyl)-2’-deoxycytidine (BVDC) [5] 
and Q-5-(2-bromovinyl)- 1 -,&D-arabinofuranosyl- 
uracil (BVaraU) [6,7], l-(2’-fluoro-2’-deoxy-l-,8- 
D-arabinofuranosyl)-5-iodocytosine (FIAC) [8,9], 
l-(2 ’ -fluoro-2 ’ -deoxy- 1-/3-D-arabinofuranosyl)-5- 
methyluracil (FMAU) [9,10] and phosphonofor- 
mic acid (PFA) [ 111. The selectivity of these com- 
+ To whom correspondence should be addressed 
pounds as inhibitors of herpes simplex virus (HSV) 
primarily depends upon a specific activation (phos- 
phorylation) by the HSV-encoded thymidine 
(dThd) kinase (TK), except for PFA [12]. Indeed, 
upon HSV infection, a virus-specified TK is in- 
duced, which differs from human cytosol and 
mitochondrial TK in its physical, immunological 
and kinetic behavior [ 131. It is endowed with de- 
oxycytidine (dCyd) kinase activity and shows a 
much greater affinity for several nucleoside ana- 
logues including ACV [14], DHPG [15], BVDU 
[16], IVDU [16], BVDC [16], BVaraU [17], FIAC 
[ 171 and FMAU [ 171, than the cellular (cytosol) 
TK. The fact that these compounds are intensively 
phosphorylated by the viral TK, and only to a very 
limited, and often undetectable, extent by the 
cellular TK, apparently accounts for their low level 
of toxicity for the uninfected host cell. 
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We have previously described a thymidylate syn- 
thetase (TS)-deficient mutant cell line (designated 
FM3A/TS-) which was derived from mutagenized 
murine mammary carcinoma FM3AI’O cells 
[l&21]. This mutant cell line, which is auxo- 
trophic for dThd appeared very useful to 
distinguish those pyrimidine rmcleoside analagues 
that are, like dThd, incorporated into host cell 
DNA and stimulatory for cell growth from those 
nucleoside analogues that are not t20,2I ]. We have 
now constructed a TK-deficient FM3A cell line 
(FM3A TK-) which was subsequently transformed 
by a fragment of HSV-1 DNA containing the gene 
for TK (hence designated FM3A TK-IHSV-1 
TKf). A broad variety of both selective and non- 
selective antiherpet~c drugs were evaluated for 
their inhibitory effects on the growth of FM3A/O 
and FM3A TK-/HSV-1 TKt cells. Those com- 
pounds whose anti-herpes activity does not depend 
on a specific phosphorylation by the HSV-1 TK 
proved equally inhibitory to the proliferation of 
FM3AIO and FM3A TK/HSV-1 TK+ cells. Some 
(but not all) of the compounds, whose inhibitory 
effects on HSV-1 replicatian depend on a specific 
phosphorylation by the viral TK were much more 
inhibitory to the growth of FM3A TK-/HSV-1 
TK+ than F1M3Ar’O cells. For example, BVDU in- 
hibited the growth of FM3A TK/HSV-1 TK” and 
FM3A/O cells at 0.5 ng/ml and 11.4 @g/ml, 
respectively. Thus, transformation of the FM3A 
cells with the HSV-1 TK gene increased the 
cytostatic activity of BVDU 22800-fold. 
2. MATERIALS AND METHODS 
2.1. Cells: growth conditions, origin and selection 
Murine FM3A cells (subclone F28-7), originalIy 
established from a spontaneous mammary car- 
cinoma in a C3H/He mouse 1221 and designated 
FM3A/O, were grown in 75-cm* tissue culture 
flasks (Sterilin, Teddington, England) in Eagle’s 
MEM, supplemented with 10% (v/v) inactivated 
fetal calf serum (Gibco Bio-Cult, Glasgow, 
Scotland), 2 mM L-glutamine (Flow Laboratories, 
Irvine, Scotland) and 0.075% (w/v) NaHC03 
(Flow Laboratories). FM3A/TS cells were main- 
tained in the same culture medium, supplemented 
with 20r_1M dThd [20,21]. 
The FM3A TK-/HSV-1 TK+ cell line, which 
lacks host cell TR activity but contains the HSV-I 
TK gene, was originally derived from a subclone of 
FM3A/O cells, made deficient for host cell TK by 
selection in the presence of 5-bromo-2’-deoxyuri- 
dine (BDU), The HSV-I TK gene was introduced 
by DNA-mediated gene transfer using pBR322 
plasmid containing the 3.6-kb BarnHI fragment of 
HSV-1 DNA at a &mHI site. The plasmid clone 
used for transformation did not contain the genes 
for viral DNA polymerase or ribonucteotide 
reductase. 
From the FM3A TK-/HSV-1 TK+ cells a TS- 
deficient subclone was derived as in [22]. Shortly, 
FM3A TK-/HSV-1 TK’ cells were mutagenized 
with I @g/ml N-methyl-N’-nitro-N” -nitrosoguani- 
dine for 3 h at 37°C. The cells were grown for 5 
days in the presence of IOe5 M dThd, and then 
plated on agarose in the presence of 1O-6 M 
5-methyltetrahydrofolate, 2 x 10F7 M metho- 
trexate and 10s5 M dThd. FM3A TK-/HSV-1 
TK*/TS- colonies were isolated after IO days. 
FM3A TK-/HSV-1 TK’ and FM3A TK-IHSV-I 
TK’/TS- cells were cultured in the same medium 
as FM3A/O and FM3A/TS cells, i.e., in the 
absence or presence of 20pM dThd, respectively. 
The source of the test compounds was as 
follows: BVDU and IVDLJ, synthesized by R. 
Busson and H. Vanderhaeghe of the Rega Institute 
for Medical Research (Katholieke Universiteit 
Leuven, E-3000 Leuven), following a modification 
of the method described by Jones et al. ]23]; 
BVaraU, provided by H. Machida (Yamasa Shoyu 
Co., Choshi, Japan), see also {24]; BVDC, provid- 
ed by R.T. Walker (University of Birmingham, 
Birmingham, England); see also [23]; ACV, Bur- 
roughs Wellcome Co. (Research Triangle Park, 
NC); the &-iodo derivative of ACV (IACV), pro- 
vided by M.J. Robins (University of Alberta, Ed- 
monton, Canada), see also [25]; FIAC and 
FMAU, provided by J.J. Fox (Sloan-Kettering In- 
stitute, New York, NY), see also [9,10]; DHPG, 
provided by J.P.H. Verheyden (Syntex Research, 
Palo Alto, CA); 5-(2-chloroethyl)-2 ’ -deoxyuridine 
(CEDU), provided by B. Rosenwirth (Sandoz 
Forschungsinstitut, Vienna, Austria), see also [26]; 
I-,8-D-arabinofuranosylthymine (araT), provided 
by H. Machida (Yamasa Shoyu Co., Choshi, 
Japan); 5-ffuoro-2’-deoxyuridine (FDU), Aldrich 
(Milwaukee~ WI); BDU, Sigma Chemical Com- 
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pany (St. Louis, MO}; 5-i~do-2’-deoxyuridine 
(IDU), Sigma; 5-trifluoromethyl-2’-deoxyu~idine 
(TFT), P-L Biochemicals (Milwaukee, WI); 
5-ethyl-2’-deoxyuridine (EDU), Robugen GmbH 
(Esslingen, FRG), see also [27,28]; 5-propyi-2’- 
deoxyuridine (PDU), [29]; 9-~-D-arabinof~rano- 
syladenine (araA), Sigma; S-~-D-arabin~fnrano- 
sylcytosine (arae), Upjohn Company (Puurs, 
Belgium); and PFA, provided by B. Gberg {Astra 
LHkemedel AB, Sfidertglje, Sweden). The thera- 
peutic potentials of these anti-herpes agents have 
been reviewed in [30,31]. 
TK” than of FM3A/O cells; i.e., BVDU 
(22 800-fold), BVDC (20250-fold), IVDU 
(56~-fold), araT (67%fold) and DHPG 
(130-fold). Clearly, phosphorylation of these com- 
pounds by the viral TK is required for their in- 
hibitory effect on the growth of HSV-1 trans- 
formed cells. Although obligatory, this phospho- 
rylation may not be sufficient for a cytostatic 
effect of the anti-herpes agents on HSV-1 trans- 
formed cells, since several other compounds, 
ACV, FMAU, EDU and BVaraU, which also 
2.3. Inhibition of tumor cell growth Table 1 
All assays were performed in 96-multiwe 
microtest piates (Falcon, Becton Dickinson, Ox- 
nard, CA). To each well were added 5 x IO” cells 
and varying amounts of the test compounds. The 
cells were then allowed to proliferate at 37°C in a 
humidified, COz-controlled atmosphere. In 
preliminary assays it was assessed that the growth 
of the cells was linear for up to 72 h. In the cell 
growth-inhibition experiments, the incubation was 
stopped at 48 h. The cells were then enumerated in 
a Couher Counter (Coulter Electronics, Harpen- 
den, England). The cell growtb-inhibitory effects 
of the test compounds are expressed in Z&O, or the 
inhibitory dose required to reduce the final cell 
number by 50010. 
Inhibitory effects of anti-herpes agents on the 
proliferation of FM3A/O and FM3A TK-/HSV-i TK+ 
cetis 
Com- 
pound’ 
I&0 tuglmi) z&3 
(FM3A/O) 
FM3A/O FM3A TK-I l&o (FM3A 
HSV-1 TK+ TK-IHSV-1 
TK+) 
Selective anti-herpes agents 
BVDU 11.4 
BVDC 16.2 
IVDU 2.80 
0.0005 22 800 
0.~8 20250 
0.0005 5600 
3. RESULTS AND DISCUSSION 
3.1. Inhibitory effects of u~ti-Hermes agents on the 
proliferation of FM3A/O and FM3A TK-I 
HSV-I Tic;’ cells 
A wide series of anti-herpes agents were 
evaluated for their inhibitory effects on the growth 
of FM3A/O and FM3A TK-IHSV-I TK’ cells 
(table 1). Based on whether the compounds act as 
preferential substrates for the HSV-1 TK [12], 
distinction was made between selective and non- 
selective ~ti-herpesvirus agents (although it 
should be recognized that some of the compounds 
belonging to the latter category, i.e., araA and 
PFA, may interact specifically with the viral DNA 
poiymerasef ” 
araT 238 0.351 
DHPG 37.5 0.288 
FMAU 5.92 1.20 
ACV 27.2 7.32 
IACV 180 74 
FIAC >lOO > lob 
CEDU 35.4 >lOb 
EDU 9.47 > lob 
BVaraU >300 > 300 
PDU >lOOO > 1000 
Non-s~ie~tive anti-herpes agents 
araA 15.4 3.72 4.1 
TFT 0.007 0.004 1.7 
PFA 221 137 1.6 
araC 0.211 0.150 1.4 
FDU 0.0005 0.~06 0.8 
BDU 38.5 620 0.06 
IDU 7.38 454 0.02 
Among those compounds whose anti-herpes ac- 
tivity depends on a specific ~hosphorylation by the 
viral TK, several congeners were much more in- 
hibitory to the proliferation of FM3A TK-/HSV-1 
a Considered as ‘selective’ if preferentially phos- 
phorylated by the WSV-1 TK [I21 
b ~L?SO value could not be measured accurately within the 
concentration range of lO-lO~~g/~~l 
678 
130 
4.9 
3.7 
2.4 
- 
- 
- 
- 
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depend on a specific phosphorylation by the viral 
TK, were found not to inhibit FM3A TK-/HSV-1 
TK+ cell growth to a significantly greater extent 
than FM3A/O cell growth. The contrast between 
BVDU and BVaraU is particularly striking. Both 
compounds are equally inhibitory to HSV-1 re- 
plication in human fibroblast cell cultures [6]. 
Nevertheless, BVDU is inhibitory to the replication 
of HSV-l-transformed FM3A cells at a concentra- 
tion of 0.5 ng/ml, whereas BVaraU does not affect 
the growth of these cells even at 300pg/ml. 
It is not yet clear why there are such dramatic 
differences in the cytostatic potencies of the selec- 
tive anti-HSV-1 agents for HSV-l-transformed 
cells. All these agents inhibit an acute HSV-1 infec- 
tion within the concentration range of 0.5-0.005 
pug/ml [l-lo]. Yet, their IDSO for HSV-l-trans- 
formed cells varies over more than a 106-fold 
range. The relatively poor activity of ACV, IACV, 
FMAU and FIAC, and inactivity of BVaraU and 
PDU, as inhibitors of HSV-l-transformed cell 
growth may be related to several factors; i.e., these 
compounds may not be adequately phosphorylated 
within the transformed cells, or, if they are, they 
may fail to reach the target(s) for a cytostatic 
action. 
It is tempting to correlate the cytostatic effects 
of BVDU, BVDC and IVDU on HSV-l-trans- 
formed cells to their incorporation into the host 
DNA, and, conversely, to attribute the inactivity 
of BVaraU to a lack of incorporation into cell 
DNA. Analogues of I-P-D-arabinofuranosyluracil 
(araU) are, in general, very poor substrates for 
DNA polymerase, and do not act as an alternate 
substrate for DNA elongation in the absence of 
dTTP. This has been shown directly for a series of 
j-substituted araUTP analogues [32] as well as 
BVaraUTP [7,33]. Thus, the incorporation of the 
nucleoside analogues into host cell DNA may be a 
critical determinant in their cytostatic action. 
Whether the compound is incorporated within the 
interior of the DNA chain or at the 3 ‘-terminal is 
another important consideration. Compounds like 
BVDU, FIAC and DHPG can be incorporated via 
an internucleotide linkage [12,13,34], and, conse- 
quently, their incorporation may be irreversible. In 
contrast, ACV and BVaraU are incorporated only 
at the 3’-terminal [7,13,35], and such an incor- 
poration may be reversible, since endonucleases 
could remove terminal oligonucleotides containing 
98 
ACV or BVaraU. It would now seem mandatory to 
investigate to what extent the different compounds 
are processed, phosphorylated, metabolized and 
incorporated into DNA of HSV-l-transformed 
cells. 
As expected, those compounds whose potent 
anti-herpes activity does not depend on a specific 
phosphorylation by the HSV-1 TK proved equally 
cytostatic for FM3A/O and FM3A TK-/HSV-1 
TK+ cells (table 1). In fact, BDU and IDU were 
even more inhibitory to the proliferation of 
FM3A/O than of FM3A TK-/HSV-1 TKf cells. 
Perhaps a decreased phosphorylation of these 
compounds by the FM3A TK-/HSV-1 TK+ cells 
may account for the decreased cytostatic activity, 
since FM3A TK-/HSV-1 TKf cells possess only 
35.6% of the TK activity expressed in FM3A/O 
cells (in preparation). 
3.2. Stimulatory effects of anti-herpes agents on 
the proliferation of FM3A/TS- and 
FM3A TK-/HS V-I TK+/TS cells 
Based on the premise [20,21] that stimulatory ef- 
fects of dThd analogues on the growth of dThd- 
auxotrophic FM3A/TS cells may be considered 
as indicative for their incorporation into host cell 
DNA, all the compounds listed in table 1 were ex- 
amined for their capacity to substitute for dThd in 
sustaining the growth of FM3A TK-/HSV-I 
TK+/TS cells. Only BDU and IDU were able to 
do so (at -lO,ug/ml; not shown). BVDU, BVDC, 
IVDU, araT and DHPG were unable to sustain the 
growth of FM3A TK-/HSV-1 TK+/TS cells. Ap- 
parently, their potential to stimulate the growth of 
these TS cells was counteracted by their cytostatic 
action, as already evident from their inhibitory ef- 
fect on the growth of FM3A TK-/HSV TK+ cells 
(table 1). ACV, IACV and BVaraU were also 
unable to sustain growth of the FM3A 
TK-/HSV-1 TK+/TS- cells, probably because 
they act as DNA chain terminators. FDU, TFT 
and PDU, which have been shown to be unable to 
sustain the growth of FM3A/TS cell growth [21], 
did not sustain the growth of FM3A TK-/HSV-I 
TK+/TS cells either. 
4. CONCLUSION 
The major observation emerging from these 
studies is the highly potent and selective cytostatic 
Volume 185, number 1 FEBS LETTERS June 1985 
effect of BVDU, BVDC and IVDU, at concentra- 
tions as low as OS-O.8 ng/ml, on murine mam- 
mary carcinoma cells transformed with the HSV-1 
TK gene. While the exact mechanism by which 
BVDU achieves this inhibitory activity is subject to 
further study, the fact that transformation of 
tumor cells with the HSV-1 TK gene makes them 
exquisitely sensitive to the cytostatic action of such 
selective anti-herpes drugs as BVDU may have far- 
reaching implications, both fundamental and 
therapeutic. 
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